LeadStory

CNBC

GLP-1 obesity pills face off in head-to-head trial

CNBC · New
CNBC
CNBC
New

CNBC's Angelica Peebles joins 'Money Movers' to discuss the battle between Eli Lilly and Novo Nordisk over GLP-1 obesity pills.

Breakdown
  • Eli Lilly and Novo Nordisk will soon conduct a head-to-head trial of their GLP-1 obesity pills. 33s
  • Lilly's pill recently showed less weight loss than hoped, shifting investor attention to Novo Nordisk. 22s
  • Analysts predict oral GLP-1 drugs could capture 20% of the obesity drug market by 2030. 1m 23s
  • Injectable drugs are expected to remain more effective than pills for significant weight loss. 1m 51s
  • Novo Nordisk is seeking FDA approval to add cardiovascular benefits to its oral drug label. 2m 42s
HealthBusiness